[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/04, WED) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 프레제니우스, 中우시와 '시밀러 37개' 개발 "옵션딜" 
[https://www.biospectator.com/news/view/30283](https://www.biospectator.com/news/view/30283)

 HLB, ‘리보세라닙’ FDA 허가결정 내년 4월9일까지
[https://www.biospectator.com/news/view/30292](https://www.biospectator.com/news/view/30292)

 삼성에피스, 테바와 '시밀러' 2종 美판매 "4.2억弗 딜"
[https://www.biospectator.com/news/view/30291](https://www.biospectator.com/news/view/30291)

 테바, 'α-Syn 저해제' MSA 2상 중단.."효능 이슈"
[https://www.biospectator.com/news/view/30278](https://www.biospectator.com/news/view/30278)

 셀트리온, '비만 4중작용제' 비임상결과 "유럽학회 발표" 
[https://www.biospectator.com/news/view/30290](https://www.biospectator.com/news/view/30290)

 10월 비상장 바이오투자, 2곳 513억.."높아진 허들" 
[https://www.biospectator.com/news/view/30276](https://www.biospectator.com/news/view/30276)

 애브비, 中브리즈 '편두통 에셋' 2개 "7.57억弗 L/I"
[https://www.biospectator.com/news/view/30285](https://www.biospectator.com/news/view/30285)

 티움, 'TGFβRI/VEGFR2' 두경부암 "美패스트트랙 지정"
[https://www.biospectator.com/news/view/30298](https://www.biospectator.com/news/view/30298)

 애브비, 'TGFβ-GARP 항체' 폐암 2상 "중단이유 공개"
[https://www.biospectator.com/news/view/30295](https://www.biospectator.com/news/view/30295)

 SK바팜, '세노바메이트' 신규 적응증 "FDA 허가신청"
[https://www.biospectator.com/news/view/30297](https://www.biospectator.com/news/view/30297)

 KASBP ‘신약 진화’ 4가지 톱픽 “25주년 가을 심포지엄” 
[https://www.biospectator.com/news/view/30289](https://www.biospectator.com/news/view/30289)

 루닛, 477억 규모 CB 발행 결정.."고금리 CB 대환"
[https://www.biospectator.com/news/view/30301](https://www.biospectator.com/news/view/30301)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/04, WED) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)